College
College of Arts and Sciences
Mentor Information
Dr. Hector Gomez & Ms. Semene Clement
Description
Biomarkers indicate physiological processes that predict cancer therapeutic responses. Tumor progression relies on immune evasion and angiogenesis within the microenvironment. The programmed cell death protein-1 (PD-1/PD-L1) pathway suppresses CD8+ T-cell activity, while vascular endothelial growth factor (VEGF) promotes tumor growth and immunosuppression. Biomarkers such as PD-L1 expression, circulating VEGF, and CD8+ T-cell infiltration reflect reliance on these mechanisms and may predict clinical responses to combined PD-1/VEGF inhibition.
This review evaluates how combined inhibition of the PD-1 and VEGF pathways modulates tumor microenvironment dynamics and assesses biomarkers associated with angiogenesis to predict responses to anti-angiogenic therapies. A total of 147 credible articles published within the past five years were screened and narrowed to 47 using predefined inclusion and exclusion criteria.
Across the reviewed studies, combined PD-1 and VEGF inhibition demonstrated a synergistic effect in the tumor microenvironment. VEGF inhibition resulted in vascular normalization, reduced hypoxia, and decreased levels of VEGF, microvessel density, and immunosuppressive cells. PD-1 inhibition restored cytotoxic T-cell function and increased the density of CD8+ T cells. In preclinical trials, combined pathway inhibition led to reduced tumor growth and density in experimental groups compared to controls, accompanied by decreased VEGFA and PD-L1 expression.
Overall, combined PD-1 and VEGF inhibition may reshape the tumor microenvironment by enhancing immune infiltration and reducing angiogenesis, thereby improving treatment response. Biomarkers of immune activation and vascular changes may help indicate therapeutic efficacy. Future studies should assess long-term outcomes, optimal dosing, resistance mechanisms, and validate predictive biomarkers.
Combined PD-1 and VEGF Pathway Inhibition: Effects on Tumor Microenvironment Dynamics and Predictors of Therapeutic Response
Biomarkers indicate physiological processes that predict cancer therapeutic responses. Tumor progression relies on immune evasion and angiogenesis within the microenvironment. The programmed cell death protein-1 (PD-1/PD-L1) pathway suppresses CD8+ T-cell activity, while vascular endothelial growth factor (VEGF) promotes tumor growth and immunosuppression. Biomarkers such as PD-L1 expression, circulating VEGF, and CD8+ T-cell infiltration reflect reliance on these mechanisms and may predict clinical responses to combined PD-1/VEGF inhibition.
This review evaluates how combined inhibition of the PD-1 and VEGF pathways modulates tumor microenvironment dynamics and assesses biomarkers associated with angiogenesis to predict responses to anti-angiogenic therapies. A total of 147 credible articles published within the past five years were screened and narrowed to 47 using predefined inclusion and exclusion criteria.
Across the reviewed studies, combined PD-1 and VEGF inhibition demonstrated a synergistic effect in the tumor microenvironment. VEGF inhibition resulted in vascular normalization, reduced hypoxia, and decreased levels of VEGF, microvessel density, and immunosuppressive cells. PD-1 inhibition restored cytotoxic T-cell function and increased the density of CD8+ T cells. In preclinical trials, combined pathway inhibition led to reduced tumor growth and density in experimental groups compared to controls, accompanied by decreased VEGFA and PD-L1 expression.
Overall, combined PD-1 and VEGF inhibition may reshape the tumor microenvironment by enhancing immune infiltration and reducing angiogenesis, thereby improving treatment response. Biomarkers of immune activation and vascular changes may help indicate therapeutic efficacy. Future studies should assess long-term outcomes, optimal dosing, resistance mechanisms, and validate predictive biomarkers.
